![]() ![]() Expansion of tumor tissue on 3D scaffolds for successful Vigil constructionĪbout Vigil Vigil® is a novel, triple function immunotherapy platform that modifies a patient’s tumor by using bi-shRNA to reduce furin, an enzyme which facilitates immunosuppressive TGF beta protein production, and to maximize DNA expression of GM-CSF, which stimulates the immune system and attracts key immune system effector cells, including T cells.Successful cell growth and re-expansion of a murine colorectal carcinoma cell line: Following initial expansion on 3D scaffolds, cells were able to be isolated and re-expanded on a greater number of scaffolds to achieve increased cell harvest.Proof of Principle was demonstrated for a large-scale 3D scaffold platform: Uniform fibrinogen deposition was achieved using a double coating process.The full text of the article can be found here. This could expand the treatment opportunity of Vigil to a much larger population and across further indications.”Īdditional testing is ongoing in human tissue in preparation for IND development and Vigil clinical testing involving cancer patients with minimal resectable disease. The magnitude of cell expansion would enable Vigil product to be constructed from much smaller tumor masses, potentially eliminating the need for surgical extraction and enabling a safer procedure for initial tumor harvest. John Nemunaitis, MD., CSO of Gradalis, commented, “We look forward to utilizing this technology to further advance Vigil, a novel, personalized cellular immunotherapy platform that is designed to decloak the full repertoire of a patient’s tumor antigens, reactivate the immune system, and summon key effector cells to deliver a durable anticancer clinical response. The polymer scaffold is then coated with selected EHD proteins such as fibronectin to form a unique engineered extracellular matrix (ECM) for further growth optimization. Electrohydrodynamic (EHD) co-jetting is conducted to print hyper-porous polymer frameworks of stacked polymer fibers, creating 3D compartments that can be optimized for growth advantage. The scaffold technology developed by the Lahann Lab, is a modular tissue engineering system with the ability to precisely control mechanical properties, protein composition and cellular constituents of cancer cellular growth and survival. Further, results demonstrated that murine colorectal carcinoma cells grown on 3D scaffold rapidly reached a 38-fold increase and generally maintained their RNA expression profile.” “Compared to conventional tissue culturing systems, our system leverages a new coating process that successfully mimics the tumor microenvironment and enables large platform scalability. “We are encouraged by the transformational work that has advanced our 3D scaffold framework for the optimization of cellular growth, which has broad potential clinical applications,” said Joerg Lahann, PhD Director, Biointerfaces Institute and Wolfgang Pauli Collegiate Professor of Chemical Engineering. The publication entitled, “A Scalable Engineered Extracellular Matrix Platform to Expand Tumor Cells,” provides proof of principle for a large-scale three-dimensional (3D) platform that is designed for high throughput cell proliferation with clinical applications and potential use for Vigil product construction. announced the peer-reviewed publication in Advanced NanoBioMed, highlighting the therapeutic applications of a new extracellular matrix platform developed for tumor cell expansion in collaboration with the University of Michigan Biointerfaces Institute. Technology developed in collaboration with the Lahann lab at Biointerfaces Institute at the University of MichiganĭALLAS, J(GLOBE NEWSWIRE) - Gradalis Inc.Demonstrated successful increase in cell number by 38-fold with plans to use scaffold expanded tissue platform for future Vigil product construction.Technology leverages new coating process to create 3D scaffold matrix that is designed to mimic the tumor microenvironment and enable large scale tumor cell expansion. ![]()
0 Comments
Leave a Reply. |